Nasdaq:ZBIO
Zenas BioPharma, Inc.
A clinical-stage biopharmaceutical firm advancing proprietary therapies in oncology and rare diseases with a robust balance sheet supporting R&D execution.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted by the company's extensive cash reserves of $319.7M which provide ample runway to advance multiple clinical candidates without immediate pressure for revenue generation. The significant capital infusion of $413.0M from financing activities suggests management is effectively securing resources to navigate the high-risk development phases typical of biotechnology firms.
Bear Case
The company faces severe financial strain with a net loss of $157.0M and negative operating cash flow of -$119.7M, highlighting an unsustainable burn rate without imminent commercial milestones. With total liabilities exceeding $57M and a retained earnings deficit of -$387.4M, the stock carries extreme volatility risks typical of pre-revenue biotech companies dependent on continuous equity issuance.
About Zenas BioPharma, Inc.
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs, primarily serving the global oncology and rare disease markets. The company leverages its proprietary technology platforms to advance multiple candidates through preclinical and clinical development stages with the aim of partnering or commercializing life-changing treatments.
Analysis
Management Discussion
The company reported a net loss of $157.0M in 2024 driven by substantial research and development expenditures of $139.1M and general administrative costs of $29.7M, resulting in operating profit of -$163.9M. However, the firm maintains a healthy cash position with $319.7M in cash and equivalents and generated $413.0M from financing activities, indicating strong capital raising capabilities to fund its pipeline.
Industry Overview
The global biopharmaceutical industry is characterized by high R&D costs and long development timelines, where successful clinical trials can lead to blockbuster revenues but failure results in total loss of invested capital. Companies like Zenas BioPharma operate in a competitive landscape requiring substantial external funding to reach commercialization.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2024 |
|---|---|
| Revenue | $5.0M |
| Cost of Revenue | $0 |
| Gross Profit | $5.0M |
| Operating Expenses | $168.9M |
| Operating Income | $-163.9M |
| R&D | $139.1M |
| G&A | $29.7M |
| Stock-Based Comp | $10.8M |
| Depreciation | $137.0K |
| Other OpEx | $0 |
| Non-Operating Income | $7.3M |
| Pre-Tax Income | $-156.6M |
| Income Tax | $429.0K |
| Continuing Ops | $-157.0M |
| Discontinued Ops | $0 |
| Net Income | $-157.0M |
| Minority Interest | $0 |
| Net to Common | $-157.0M |
| Metric | 2024 |
|---|---|
| Current Assets | $355.9M |
| Cash & Equivalents | $319.7M |
| Marketable Securities | $31.0M |
| Prepaid Expenses | $5.1M |
| Other Current Assets | $90.0K |
| Long-Term Assets | $14.0M |
| PP&E (Net) | $185.0K |
| Operating Leases | $1.0M |
| Other LT Assets | $12.9M |
| Total Assets | $370.0M |
| Current Liabilities | $57.3M |
| Accounts Payable | $17.1M |
| Current Leases | $785.0K |
| Taxes Payable | $211.0K |
| Other Current Liab | $-211.0K |
| Long-Term Liabilities | $218.0K |
| LT Operating Leases | $218.0K |
| Other LT Liab | $0 |
| Total Liabilities | $57.5M |
| Shareholders' Equity | $312.5M |
| Paid-In Capital | $699.7M |
| Retained Earnings | $-387.4M |
| AOCI | $194.0K |
| Total L&E | $370.0M |
| Metric | 2024 |
|---|---|
| Net Income (CFO) | $-157.0M |
| Non-Cash Adjustments | $-3.5M |
| Working Capital Changes | $40.8M |
| Cash from Operations | $-119.7M |
| Capital Expenditures | $131.0K |
| Cash from Investing | $-30.6M |
| Cash from Financing | $413.0M |
| FX Effect | $157.0K |
| Net Change in Cash | $262.9M |
| Beginning Cash | $56.9M |
| Ending Cash | $319.8M |
Frequently Asked Questions
How does Zenas BioPharma, Inc. make money?
Oncology Development, Rare Disease Therapeutics, Technology Platform Licensing
What are the main risks for ZBIO?
High burn rate with no current commercial revenue leading to significant dilution risks, potential failure of clinical trials for all in-development candidates, regulatory approval uncertainties, and dependence on successful external collaborations to extend cash runway.
What is ZBIO's competitive advantage?
Proprietary asset classes targeting difficult-to-treat indications, a strong balance sheet providing operational flexibility without near-term commercial revenue pressure, and strategic partnerships that de-risk development timelines.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.